Program
Wednesday, June 24
Thursday, June 25
- Plenary Session 2: Next Generation Clinical Assessment
- Plenary Session 3: The Lymphoma Microenvironment
- Plenary Session 4: Spatial Analysis of Lymphoma
Friday, June 26
- Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma
- Plenary Session 6: Degraders in Lymphoma
- Plenary Session 7: Rare Lymphomas
- Plenary Session 8: Advances in Cell Therapy
Saturday, June 27
- Closing Keynote Lecture
- Plenary Session 9: Germinal Center Biology and Lymphomas
- Plenary Session 10: Epigenetics
Wednesday, June 24
REGISTRATION
1-7 p.m.
WELCOME AND OPENING Keynote
- Opening Keynote Lecture
Ron Levy, Stanford University, Stanford, California
Plenary Session 1: Antibodies through the eras
- Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, New York
Thursday, June 25
Plenary Session 2: Next Generation Clinical Assessment
- Davide Rossi, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
- Genetics to inform therapy in lymphoma
Margaret Shipp, Dana Farber Cancer Institute, Boston, Massachusetts - Integrating the microenvironment and omics into clinical workflows
Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
Plenary Session 3: The Lymphoma Microenvironment
- Sandrine Roulland, Centre d’Immunologie de Marseille-Luminy, Marseille, France
- Using the microenvironment to predict response to therapy
Justin Kline, University of Chicago, Chicago, Illinois - Hodgkin lymphoma tumor microenvironment
Christian Steidl, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Plenary Session 4: Spatial Analysis of Lymphoma
- Spatial transcriptomics of DLBCL
Michael Green, The University of Texas MD Anderson Cancer Center, Houston, Texas - Transformation
Erin Parry, Dana Farber Cancer Institute, Boston, Massachusetts
Friday, June 26
Plenary Session 5: New Targeted Therapeutic Strategies in Lymphoma
- Chemotherapy-free strategies for large B-cell lymphoma
Mark Roschewski, National Cancer Institute, Bethesda, Maryland
Plenary Session 6: Degraders in Lymphoma
- Exploiting the E3 ligase FBXO21 as a novel therapeutic target and degrader in lymphoma
Shannon Buckley, University of Utah, Salt Lake City, Utah - Francesco Bertoni, Oncology Institute of Southern Switzerland, Bellinzona, Ticino, Switzerland
Plenary Session 7: Rare Lymphomas
- Jean Koff, Winship Cancer Institute of Emory University, Atlanta, Georgia
- Navigating the landscape of peripheral T-cell lymphomas
Teresa Palomero, Columbia University, New York, New York
Plenary Session 8: Advances in Cell Therapy
- Armored CAR T cells
Sarwish Rafiq, Winship Cancer Institute of Emory University, Atlanta, Georgia - Novel engineering strategies for CAR T cell therapy in lymphoma
Laura Evgin, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Saturday, June 27
Closing Keynote Lecture
- Michel Nussenzweig, Rockefeller University, New York, New York
Plenary Session 9: Germinal Center Biology and Lymphomas
- Cells of origin for lymphoma
Dinis Calado, Francis Crick Institute, London, United Kingdom - Ari Melnick, Josep Carreras Institute, Badalona, Catalonia, Spain
Plenary Session 10: Epigenetics
- Wendy Beguelin, New York University, New York, New York
- Laura Pasqualucci, Columbia University, New York, New York
